Comparative evaluation of the degree of pegylation of poly(lactic-co- glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 10, 2013, Pages 1473-1481

  Kirby, Brian P ^a,b   Pabari, Ritesh ^a   Chen, Chi Nan ^a   Al Baharna, Marwa ^a   Walsh, Jeremy ^a   Ramtoola, Zebunnissa ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b PERDANA UNIVERSITY   (Malaysia)

Author keywords

biodegradable polymers; blood brain barrier; CNS; nanoparticles; pegylated PLGA

Indexed keywords

COUMARIN 6; COUMARIN DERIVATIVE; LOPERAMIDE; MACROGOL; NANOPARTICLE; POLYGLACTIN; POLYGLACTIN NANOPARTICLE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CELL STRAIN CACO 2; CELL TRANSPORT; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CHEMICAL MODIFICATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG FORMULATION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; EVAPORATION; FEMALE; FLOW CYTOMETRY; HOT PLATE TEST; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PEGYLATION; PHYSICAL CHEMISTRY; SURFACE CHARGE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

BIODEGRADABLE POLYMERS; BLOOD BRAIN BARRIER; CNS; NANOPARTICLES; PEGYLATED PLGA;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; CACO-2 CELLS; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; ENDOCYTOSIS; HUMANS; LACTIC ACID; LOPERAMIDE; MICE; MICE, INBRED C57BL; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SURFACE PROPERTIES;

EID: 84883742040     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12125     Document Type: Article

References (30)

1. Pardridge WM,. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003; 3: 90-105.
2. WHO. Neurological Disorders: Public Health Challenges. Geneva: World Health Organization, 2006.
3. Zlokovic BV,. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
4. Kreuter J, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002; 10: 317-325.
5. Kreuter J,. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65-81.
6. Tilloy S, et al. Methylated β-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier. Bioorg Med Chem Lett 2006; 16: 2154-2157.
7. Batrakova EV, et al. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 2001; 296: 551-557.
8. Chen Y, Liu L,. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 2012; 64: 660-665.
9. Wong HL, et al. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2011; 64: 686-700.
10. Tosi G, et al. Polymeric nanoparticles for the drug delivery to the central nervous system. 2008.
11. Desai MP, et al. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14: 1568-1573.
12. Ramtoola Z, et al. Investigation of the interaction of biodegradable micro-and nanoparticulate drug delivery systems with platelets. J Pharm Pharmacol 2011; 63: 26-32.
13. Costantino L, et al. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release 2005; 108: 84-96.
14. Tosi G, et al. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007; 122: 1-9.
15. Li J, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011; 32: 4943-4950.
16. Gelperina S, et al. Drug delivery to the brain using surfactant-coated poly (lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 2010; 74: 157-163.
17. Pamujula S, et al. Cellular delivery of PEGylated PLGA nanoparticles. J Pharm Pharmacol 2012; 64: 61-67.
18. Vega E, et al. Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery. Int J Nanomedicine 2012; 7: 1357-1371.
19. Giannavola C, et al. Influence of preparation conditions on acyclovir-loaded poly-d, l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003; 20: 584-590.
20. Chen YC, et al. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier. J Biomater Appl 2013; 27: 909-922.
21. Liu Z, et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 2013; 34: 3870-3881.
22. Matsuo K, et al. Intranasal immunization with poly(gamma-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Release 2011; 152: 310-316.
23. Emerich DF, et al. Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7). Brain Res 1998; 801: 259-266.
24. Dunne M, et al. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 2000; 21: 1659-1668.
25. Siahi-Shadbad MR, et al. Release behaviour of propranolol HCl from hydrophilic matrix tablets containing psyllium powder in combination with hydrophilic polymers. AAPS PharmSciTech 2011; 12: 1176-1182.
26. De Rosa R, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A 2005; 102: 3811-3816.
27. Walsh J, et al. Disruption of thermal nociceptive behaviour in mice mutant for the schizophrenia-associated genes NRG1, COMT and DISC1. Brain Res 2010; 1348: 114-119.
28. Moghimi SM, et al. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283-318.
29. Privalova A, et al. Intranasal administration: a prospective drug delivery route to the brain. Neurochem J 2012; 6: 77-88.
30. Vij N, et al. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnology 2010; 8: 22